TPTX - Bristol Myers U.S. German antitrust filings for Turning Point expected very soon (update)

• Update 11:20am: Adds German filing from late Thursday.
• Bristol Myers  Squibb ( NYSE: BMY ) is reportedly expected to make antitrust filings to U.S. and German authorities "imminently" for its planned $4.1 billion purchase of Turning Point Therapeutics ( NASDAQ: TPTX ), according to a Dealreporter item.
• The companies notified German regulators on Thursday, according to the antitrust authorities' website.
• The acquisition remains on track for a Q3 closing, according to the report, which cited sources familiar.
• The deal update comes after BMY on Tuesday extended the tender offer for its acquisition of Turning Point Therapeutics ( TPTX ) to Aug. 15.
• BMY agreed to acquire the clinical-stage precision oncology biotech Turning Point ( TPTX ) at a price of $76.00 per share in cash for a total consideration of $4.1B early last month.

For further details see: